Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

5 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Response - Phase II Breast Cancer - Summary Response/Progression Form for Solid Tumors - 2582834v1.0 - Phase II Breast Cancer - Summary Response/Progression Form for Solid Tumors

- 08/01/15 - 1 modulo, 4 itemgroups, 25 elementi, 1 linguaggio
Itemgroups: CRF Header, Form Administration, Response Assessment, Comments
Phase II Breast Cancer - Summary Response/Progression Form for Solid Tumors Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=25794336-1BEF-04E8-E044-0003BA3F9857

ECOG Nontarget Lesions Supplemental Form (E2100)

- 28/07/15 - 1 modulo, 4 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: ECOG clinical trial administrative data, NONTARGET LESIONS, Comments, CCRR MODULE
ECOG Nontarget Lesions Supplemental Form (E2100) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AC328486-403E-246F-E034-0003BA12F5E7

NSABP Protocol B-40 - Tumor Response Form NCT00408408

- 05/07/15 - 1 modulo, 5 itemgroups, 25 elementi, 1 linguaggio
Itemgroups: Header, Form completed by, Section A: Evaluation of Target Lesions, Section B: Evaluation of NonTarget Lesions, Section C: Manifestations of Progressive Disease
NSABP Protocol B-40 - Tumor Response Form NCT00408408 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B7DC2CF-E4EE-1B7D-E044-0003BA3F9857

CALGB_40302_FU_SOL_TUM_EVAL_FRM NCT00390455

- 08/06/15 - 1 modulo, 6 itemgroups, 34 elementi, 1 linguaggio
Itemgroups: Header, Patient demographics, REPORTING PERIOD, NON-TARGET LESION(S) FOLLOW-UP EVALUATION, NEW LESION(S) AT FOLLOW-UP EVALUATION, OVERALL RESPONSE
CALGB 40302 FOLLOW-UP SOLID TUMOR EVALUATION FORM NCT00390455 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F593450E-79E6-42E1-E034-0003BA3F9857

CALGB: 49808 RESPONSE/PROGRESSION FORM NCT00016276

- 03/06/15 - 1 modulo, 4 itemgroups, 26 elementi, 1 linguaggio
Itemgroups: CALGB clinical trial administrative data, Patient clinical trial data, Response Assessment (Clinical/Radiographic), Comments
CALGB: 49808 RESPONSE/PROGRESSION FORM NCT00016276 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9E35395C-867B-227A-E034-080020C9C0E0

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial